An interactive voice application’s assessment of patient well-being through analysis of their speech was highly comparable with physicians’ tracking of patient well-being, according to a study published online in PLOS One.
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
Alkermes plc is expanding its New Drug Application (NDA) for the investigational drug ALKS 3831—a combination of the antipsychotic olanzapine and the novel molecular entity samidorphan—to include the treatment of bipolar I disorder as well as schizophrenia, the drugmaker recently announced.
Lumateperone, an investigational drug from Intra-Cellular Therapies, Inc., posted varied results in two phase 3 clinical trials evaluating it as a monotherapy for major depressive episodes associated with bipolar disorder.
SAN FRANCISCO—The antipsychotic cariprazine was effective in improving depressive symptoms in patients with bipolar depression and concurrent manic symptoms, according to a poster presented at the American Psychiatric Association’s annual meeting.
SAN FRANCISCO—Tardive dyskinesia (TD) is strongly linked with older age, medical comorbidity, and hospitalizations, according to a study of US veterans with serious mental illness presented during a poster session at the American Psychiatric Association’s annual meeting.